

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Eli Lilly launches first and only RET inhibitor for patients with metastatic solid tumours in India

25 June 2026 | News

Available in India in 40 mg, 80 mg, 120 mg and 160 mg tablet strengths; administered orally twice daily



Eli Lilly and Company India has announced the launch of Tanstrive® (selpercatinib) in India, following marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for patients with locally advanced or metastatic solid tumours with a rearranged during transfection (RET) gene.

Tanstrive® (selpercatinib) is designed to selectively target RET alterations and block the abnormal signalling pathways that drive tumour growth.

As an oral therapy administered twice daily, Tanstrive® (selpercatinib) offers a targeted treatment approach for eligible patients whose cancers are driven by RET alterations.

By targeting the underlying molecular drivers of disease, Tanstrive® (selpercatinib) supports precision treatment based on biomarker identification and has demonstrated rapid and durable responses, including meaningful activity in patients with central nervous system (CNS) involvement.

Tanstrive® (selpercatinib) is a prescription medicine used to treat certain cancers caused by abnormal RET genes in:

- Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion.
- Adult and paediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, who require systemic therapy.
- Adult and paediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
- Adult and paediatric patients 2 years of age and older with locally advanced or metastatic solid tumours with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.